Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by juniper88on Dec 03, 2018 11:54am

85 Views

Post# 29054495

RE:RE:RE:RE:RE:New CCO

"We have found in Jovan a unique blend of large and small pharma marketing and sales experience in North America, Europe and Asia, coupled to a strong understanding of the intricacies of injectable treatments and a deep knowledge of HIV. He will be able to use all these skills in his new position at Theratechnologies," concluded Mr. Tanguay.

Where did Jovan get his "deep knowledge of HIV" from, if he doesn't seem to have it on his resume?

Bullboard Posts

Advancing flagship Ishkõday Gold Project in Ontario